Geron Price Still Moving Smartly Upward
Geron rose sharply again today, closing at $8.15, up 15 percent for the day.
Barrons reported that Needham Research upgraded its recommendation on Geron from hold to buy with a $9 price target. Needham said "significant unmet needs" exist "in the management of spinal-cord injuries."
Needham also said that Geron previously reported it had $165 million ava…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.